Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 9. Nadolol: A new long-acting beta-adrenoceptor blocking drug
- 31 January 1980
- journal article
- review article
- Published by Elsevier in American Heart Journal
- Vol. 99 (1), 124-128
- https://doi.org/10.1016/0002-8703(80)90322-1
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applicationsAmerican Heart Journal, 1979
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effectsAmerican Heart Journal, 1979
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic propertiesAmerican Heart Journal, 1979
- Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertensionCurrent Medical Research and Opinion, 1978
- Metabolic Studies in Patients with Nadolol: Oral and Intravenous AdministrationThe Journal of Clinical Pharmacology, 1977
- Possible basis of antiarrhythmic action of a new beta-adrenergic blocking compound, SQ11725 (Nadolol)The American Journal of Cardiology, 1976
- Anti-arrhythmic action of nadolol, a β-adrenergic receptor blocking agentEuropean Journal of Pharmacology, 1976
- Pharmacology of nadolol (SQ 11725), a β-adrenergic antagonist lacking direct myocardial depressionEuropean Journal of Pharmacology, 1975
- Side Effects of Hypotensive Agents Evaluated by a Self-administered QuestionnaireBMJ, 1973
- The dropout problem in antihypertensive treatment: A pilot study of social and emotional factors influencing a patient's ability to follow antihypertensive treatmentJournal of Chronic Diseases, 1970